ダウンロード数: 1818
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
59_153.pdf | 713.29 kB | Adobe PDF | 見る/開く | |
59_399.pdf | errata | 699.9 kB | Adobe PDF | 見る/開く |
タイトル: | 筋層非浸潤性膀胱癌に対するBCG/epirubicin交替膀胱内注入維持療法の有効性と安全性 |
その他のタイトル: | Efficacy and Safety of Maintenance Intravesical Instillation Therapy with Bacillus Calmette-Guerin and Epirubicin for Non-Muscle Invasive Bladder Cancer |
著者: | 池田, 勝臣 元島, 崇信 黒澤, 和宏 藤井, 陽一 宮川, 仁平 上垣内, 崇行 細田, 千尋 小松, 秀樹 岡根谷, 利一 |
著者名の別形: | Ikeda, Masaomi Motoshima, Takanobu Kurosawa, Kazuhiro Fujii, Yoichi Miyakawa, Jimpei Kamigaito, Takayuki Hosoda, Chihiro Komatsu, Hideki Okaneya, Toshikazu |
キーワード: | Bacillus Calmette-Guerin Epirubicin Maintenance therapy Intravesical instillation Nonmuscle invasive bladder cancer |
発行日: | Mar-2013 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 59 |
号: | 3 |
開始ページ: | 153 |
終了ページ: | 157 |
抄録: | The objectives of this study were to evaluate the efficacy and toxicity of maintenance intravesical instillation therapy with bacillus Calmette-Guerin (BCG) and epirubicin for non-muscle invasive bladder cancer. From April 1999 to March 2010, 27 eligible patients were enrolled in this study. After receiving one cycle of epirubicin (100 mg/100 ml) by intravesical instillation, all patients received 6 weekly alternate intravesical instillation of BCG (80 mg/50 ml) and epirubicin (50 mg/50 ml), followed by 10 monthly instillations. Among the 27 patients, 19 were men and 8 were women, with a median age of 62.4 years (range, 37-78 years). Tumor pathologic stage was pTa in 25 patients, pT1 in 2 and there were no concomitant carcinoma in situ cases. Median follow-up was 37.1 months (range, 11-82 months). The 3- year recurrence-free and progression-free survival rates were 75.3% and 96.1%, respectively. Furthermore, a high completion rate of 81.5% was achieved in this study. Adverse events of grade 3 or higher occurred in 3 patients (11.1%), 1 patient had anaphylaxis. There were no treatment-related deaths. Maintenance intravesical instillation therapy with BCG and epirubicin is a favorable therapeutic option for non-muscle invasive bladder cancer. Given the safety and benefit profile found in this study, appropriate patient selection is warranted in the future. |
著作権等: | 許諾条件により本文は2014-04-01に公開 |
URI: | http://hdl.handle.net/2433/173705 |
PubMed ID: | 23633629 |
出現コレクション: | Vol.59 No.3 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。